Business
MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer
Potential breakthrough therapeutic targets $50B+ global immunotherapy market1 CHICAGO, March 31, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced highlights from a poster presented on March 27, 2026, at the European Lung Cancer Congress 2026 (ELCC), a premier thoracic oncology forum held March 25-28, 2026, in Copenhagen, Denmark. MA
About this update from Maia Biotechnology, Inc.
[{"type":"image","alt":"MAIA Biotechnology, Inc.","displaySize":"","headline":null,"caption":"MAIA Biotechnology, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":114,"url":"https://media.zenfs.com/en/globenewswire.com/fbd77a311f7c68878bc3292efbebb483"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/jAgl2ElYsXtsex6FmAJkng--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2MA--/https://media.zenfs.com/en/globenewswire.com/fbd77a311f7c68878bc3292efbebb483","width":300,"height":114}},"lazy":false},{"type":"text","content":"Potential breakthrough therapeutic targets $50B+ global immunotherapy market1","length":77,"tagName":"p"},{"type":"text","content":"CHICAGO, March 31, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced highlights from a poster presented on March 27, 2026, at the European Lung Cancer Congress 2026 (ELCC), a premier thoracic oncology forum held March 25-28, 2026, in Copenhagen, Denmark.","length":419,"tagName":"p"},{"type":"text","content":"MAIA reports overall survival (OS) beyond two years for eight patients treated with ateganosine sequenced with cemiplimab in Parts A and B of its ongoing Phase 2 THIO-101 clinical trial in non-small cell lung cancer (NSCLC). The patients did not receive subsequent lines of therapy.","length":282,"tagName":"p"},{"type":"text","content":"The eight patients featured in the poster include:","length":50,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"1 patient in third-line (3L) therapy with survival of 33 months. Expected survival in this heavily pre-treated population is 5.8 months.2","length":137,"tagName":"p"}]},{"val":[{"type":"text","content":"4 patients in 2L therapy with survival over 30 months. Documented OS for standard of care treatment (chemotherapy or checkpoint inhibitors alone) in second-line (2L) therapy is 10.5 months.3","length":190,"tagName":"p"}]},{"val":[{"type":"text","content":"All patients have failed previous treatment (prior to THIO-101) with a checkpoint inhibitor (CPI) alone.","length":104,"tagName":"p"}]},{"val":[{"type":"text","content":"All patients completed 29-34 cycles of therapy, except for 1 patient who completed 2 cycles of therapy with survival follow-up ...